Cambridge Neuroscience

Norwood, MA 02062

SBIR Award Summary

Total Number of Awards 26
Total Value of Awards $967K
First Award Date 03/01/88
Most Recent Award Date 09/01/01

Key Personnel

Last Name Name Awards Contact
Johnson Carl D Johnson 3
Fischer James B Fischer 5
Kobayashi Kazumi Kobayashi 3
Marchionni Mark Andrew Marchionni 5
Goldin Stanley M Goldin 2
Margolin Lee D Margolin 1
Mcburney Robert N Mcburney 3
Knapp Andrew G Knapp 1
Sui Jinliang Sui 3

26 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/01 - 08/31/02

Our overall therapeutic goal is to develop a drug treatment that reduces suffering and improves quality of life for victims of peripheral neuropathies - a diverse group of neurological disorders with genetic, metabolic or toxic etiologies. Patients who suffer from peripheral neuropathy can experience loss of voluntary or involuntary motor functi...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/00 - 08/31/01

Our overall therapeutic goal is to develop a drug treatment that reduces suffering and improves quality of life for victims of peripheral neuropathies - a diverse group of neurological disorders with genetic, metabolic or toxic etiologies. Patients who suffer from peripheral neuropathy can experience loss of voluntary or involuntary motor functi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/16/00 - 10/15/00

Neuregulin(NRG) proteins have interesting, diverse biological properties, and offer opportunities to develop novel therapies. One of the long-term objectives of discovery research on NRG signalling is to identify potential clinical indications. Ultimately, recombinant human NRGs may be put to use as therapies. The overall goal of the proposed re...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/97 - 03/29/98

Our long-term objective is to develop drugs for the symptomatic treatment of peripheral neuropathies. Peripheral neuropathies are a diverse group of diseases (or syndromes) affecting a large population. Focal demyelination is known to occur in neuropathies, like Guillain-Barre Syndrome and Charcot-Marie-Tooth dis...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/02/97 - 01/01/98

Our long term objective is to generate and test lead compounds to be evaluated in future clinical trails for cancer treatment through the identification of antagonists of neuregulin-erB signalling. Our approach is based on a novel, untapped component of this signalling system - the interactio...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/94 - 03/31/95

Brain damage in stroke and in cardiac arrest results from an inadequate supply of blood to the brain, termed brain ischemia. Brain ischemia depletes the energy stores of affected brain regions and causes the excessive release of glutamate and other neurotransmitters from metabolically compromised nerve terminals. Our goal is to discover synthe...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/93 - 03/31/94

Brain damage in stroke and in cardiac arrest results from an inadequate supply of blood to the brain, termed brain ischemia. Brain ischemia depletes the energy stores of affected brain regions and causes the excessive release of glutamate and other neurotransmitters from metabolically compromised nerve terminals. Our goal is to discover synthe...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/93 - 03/31/94

DESCRIPTION (Adapted from applicant's abstract):The goal of the proposed research is to develop diagnostic reagents and new therapeutics for the cure or prevention of degenerative diseases through the isolation and analysis of human genes implicated in the pathways responsible for cell death. The investigator's approach to the identification of...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/20/92 - 08/19/93

The objective of this project is to examine the molecular changes that underlie spinal cord regeneration in the lamprey. We will identify and isolate novel growth-associated proteins (GAPS) derived from the central nervous system that are expressed during the course of normal development and subsequent to CNS injury. In higher vertebrates, GAP...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/92 - 03/31/93

DESCRIPTION (Adapted from applicant's abstract):The goal of the proposed research is to develop diagnostic reagents and new therapeutics for the cure or prevention of degenerative diseases through the isolation and analysis of human genes implicated in the pathways responsible for cell death. The investigator's approach to the identification of...

Load More